Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Carcinoma, Transitional Cell 25Urinary Bladder Neoplasms 23Ureteral Neoplasms 8Urologic Neoplasms 4Urethral Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Neoplasms 3Neoplasm Metastasis 3Urogenital Neoplasms 2Muscle Invasive Bladder Urothelial Carcinoma 2Metastatic Urothelial Cancer 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Advanced Bladder Cancer 2Urothelial Cancer 1Urologic Diseases 1Urogenital Diseases 1Urinary Bladder Diseases 1Urachal adenocarcinoma 1Triple Negative Breast Neoplasms 1Salivary Gland Neoplasms 1Renal Pelvis and Ureter Urothelial Carcinoma 1Peripheral Nervous System Diseases 1Penile Squamous Cell Carcinoma (PSCC) 1Penile Neoplasms 1Pancreatic Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms by Site 1Muscle-invasive Bladder Cancer 1

Interventions

enfortumab vedotin 2pembrolizumab 1Radiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Advanced Bladder Cancer × enfortumab vedotin × Clear all
NCT06434350 2026-03-02

Enfortumab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDATE)

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
41 enrolled
Genitourinary

Advanced Bladder Cancer

NCT07346053 2026-01-16

Chrono-EVP

British Columbia Cancer Agency

Phase 3 Not yet recruiting
224 enrolled
Genitourinary

Advanced Bladder Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡